The Government Is Fighting a Drug-Testing Company in Court Over Whether Weed Is Still a Schedule I Drug

If you use cannabis — medically, recreationally, or in that unlabeled space in between most people actually live in — the federal government is, right now, in a room in Arlington, Virginia, deciding whether the drug you use is legally the same thing as heroin. That hearing has to conclude by July 15. And this week, the party fighting hardest to keep it on schedule wasn’t a police union or a prohibitionist think tank. It was the Department of Justice, opposing a bid by a drug-testing trade group and a pharmaceutical company to pause the whole thing.

A federal agency just told a drug-testing company, in writing, that it doesn’t get a veto over cannabis policy because a rescheduling would cost it business.

The DOJ’s brief didn’t mince words. It argued the plaintiffs — the National Drug & Alcohol Screening Association and an unnamed pharmaceutical company — have “pocketbook interests served by keeping all marijuana in schedule I,” and added the line that will end up in every recap of this hearing: “Congress did not enact the CSA to provide drug screeners with a permanent source of income for testing marijuana.” It’s a genuinely unusual thing to read in a federal court filing — the government naming, plainly, that an industry has a financial stake in an outcome the science doesn’t obviously require.

Here’s the part that gets lost in a headline about “marijuana rescheduling,” and it matters if you’re trying to understand what actually changes for you: this isn’t the first move. Back on April 23, 2026, the DOJ already issued an order moving FDA-approved and state-licensed medical marijuana products to Schedule III — the same tier as ketamine and anabolic steroids, drugs with recognized medical use and lower abuse potential than Schedule I. What’s happening now, in the DEA’s expedited administrative hearing running June 29 through July 15, is the fight over whether that same downgrade extends to marijuana broadly — the plant itself, not just the pharmaceutical products made from it. Recreational cannabis, in states where it’s legal, remains Schedule I until this hearing resolves. Seven interested parties were admitted to argue their side, including four state governments and the drug-testing association now asking a court to hit pause.

If this feels like it’s been going on forever, that’s because it basically has. NORML filed the first federal petition to reschedule marijuana in 1972. It was denied. It was filed again, and denied again, across five decades and multiple administrations, each cycle repeating the same core argument — that cannabis’s Schedule I placement, reserved for drugs with “no currently accepted medical use,” never matched the medical literature or the 39 states that now allow some form of legal use. What’s different in 2026 is that an HHS scientific review actually recommended the move, a DOJ order already partially executed it, and a federal judge is now running a clock that ends in days, not years. The wheel didn’t turn faster because the science got dramatically newer. It turned because the political will to act on science that’s been sitting there for a decade finally showed up.

The states aren’t waiting for Washington to finish

While the federal hearing runs its clock, states are legislating around it in real time. On July 2, Illinois Governor JB Pritzker signed SB 3222 at a Chicago dispensary, doubling legal possession limits — 60 grams of flower, 10 grams of concentrate, 1,000mg of THC in infused products, all double the prior caps — while simultaneously locking down the products regulators consider the real public-health problem: unregulated intoxicating hemp. Delta-8, THC-P, and HHC — synthetic and semi-synthetic cannabinoids sold in gas stations and vape shops, often to anyone regardless of age, under a legal loophole created by the 2018 Farm Bill’s hemp definition — are now restricted to buyers 21 and older statewide. “Instead of letting an ambiguous marketplace keep putting people at risk,” Pritzker said, “Illinois is taking action to protect consumers of all ages, especially children, from misleading packaging and labeling.”

While the federal hearing runs its clock, states are legislating around it in real time.

That loophole is closing federally too, not just in Illinois. The DEA gave HHC its own Schedule I drug code back in May, and a federal hemp law signed in November 2025 redefines “hemp” using a “total THC” standard that will cap most infused products at a fraction of a milligram starting this November — effectively ending the Delta-8/HHC gas-station market nationwide, not just in states that legislate against it directly. If you’ve been buying gummies or vape cartridges from a smoke shop rather than a licensed dispensary because it was cheaper or didn’t require an ID check: that supply is going away this year, by federal order, regardless of what the rescheduling hearing decides about the plant itself.

What the newest science actually says — and what it doesn’t

None of this regulatory motion happens in a vacuum, and the science underneath it is more complicated than either side of the rescheduling fight tends to admit. The largest study of its kind — a Kaiser Permanente-led cohort of 463,396 adolescents, published in JAMA Health Forum and tracked from age 13 to 26 — found teens who used cannabis had roughly double the risk of later psychotic disorders and bipolar disorder compared to teens who didn’t, even after accounting for prior mental health conditions and other drug use. Lead author Kelly Young-Wolff, PhD, put it directly: “adolescents who reported cannabis use had a substantially higher risk of developing psychiatric disorders.” That’s not a reason to panic if you used cannabis as a teenager and you’re fine — it’s a population-level risk, not a individual guarantee, and most people in the study who used cannabis did not go on to develop a psychotic disorder. But it is a real, replicated signal that the adolescent brain is not the adult brain, and “cannabis is basically harmless” was always the wrong plain-language summary of a much more nuanced literature.

The other body-level cost getting more attention this year has a name most people have never heard: Cannabinoid Hyperemesis Syndrome, nicknamed “scromiting” by the ER staff who see it — cyclical, severe vomiting and abdominal pain in long-term heavy users, the kind of pain that sends people back to the emergency room again and again before anyone identifies the cause. Virginia ER visits tied to CHS rose roughly 29% from 2020 to 2024, and the World Health Organization gave it an official diagnostic code for the first time in October 2025 — recognition lagging a decade behind the emergency rooms that were already treating it. The only reliable treatment clinicians currently point to is stopping use entirely, which is its own kind of hard fact for someone using cannabis as their only functional way to manage pain, anxiety, or sleep.

That’s the tension sitting underneath this whole story, and it’s not abstract. A NORML summer intern, Dakota Helgren, wrote publicly this week about breaking her leg in a skiing accident and turning down the opioid prescription she was offered, using cannabis topicals instead. “I hate the side effects of opioids, including the feeling of being altered, drowsy, and confused,” she wrote. “I was able to drastically reduce my pain.” She’s not wrong about the risk she was weighing against — but her essay and the JAMA cohort study and the CHS case reports are all true at the same time, describing the same drug from three different vantage points. If you’re the person actually deciding what to reach for tonight — for pain, for sleep, for a craving you’re trying not to feed with something worse — none of these studies makes that decision for you. They just mean the honest answer was never “cannabis is either dangerous or harmless.” It was always: it depends on your age, your dose, your duration of use, and what you’re using it to avoid.

“I hate the side effects of opioids, including the feeling of being altered, drowsy, and confused,” she wrote.

The federal government is about to answer a narrower, more legal question — whether a plant belongs in the same schedule as heroin — and it will answer it in the next two weeks, driven in no small part by a drug-testing company’s objection that the government has now called out by name. That answer will change insurance codes, research funding, and interstate commerce rules. It will not change what CHS does to a gut that’s been hit with it for three years running, and it will not change the odds a 15-year-old’s brain is running today. Both things can be true on July 16: cannabis policy finally catching up to 2026, and cannabis science still catching up to the questions people are actually living with right now.